Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
AgenT logo — Detect Alzheimer's earlier, when it could be prevented

AgenT

Detect Alzheimer's earlier, when it could be prevented

Founded 2018 France France 39 employees Total: $2.80M Biotechnology, Health Care +1

General Information

Company Name AgenT
Founded Year 2018
Location France France
Founders / Decision Makers
Team member Team member
Employees 39
Industries Biotechnology, Health Care, Life Sciences
Business Model B2B, D2C, B2D
Revenue Model Service Fee, Licensing, Data Monetization
Social

BounceWatch is an independent company data service, not affiliated with AgenT. To contact AgenT, visit agent-biotech.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does AgenT compare?

A PDF of AgenT and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting AgenT soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About AgenT

AgenT is a pioneering life sciences startup established in 2018, headquartered in France. The company's mission, encapsulated by its slogan, "Detect Alzheimer's earlier, when it could be prevented," focuses on combating Alzheimer's disease during its silent phase. By leveraging cutting-edge multi-omics assays and advanced machine learning techniques, AgenT has identified novel blood biomarkers that indicate the earliest stages of Alzheimer's, providing a breakthrough in blood diagnostics and precision therapies.

Operating at the intersection of Biotechnology, Health Care, and Life Sciences, AgenT is poised to transform Alzheimer's detection and treatment. Their most recent funding was a €2.30M Seed Round investment secured on 01 July 2021, led by investor Bernard Majoie. This capital injection underscores confidence in their innovative approach, positioning AgenT as a compelling opportunity for investors looking to support advancements in Alzheimer’s treatment and early diagnostics.

Business keywords: Life Sciences, Alzheimer's Disease, Multi-omics Assays, Blood Biomarkers, Early Diagnosis, Precision Therapies, Healthcare Innovation

Services & Products

Blood test development for early Alzheimer's detection
Machine learning modeling for disease analysis
Multiomics biomarker research

Target Customers

Healthcare providers Neurologists Clinical researchers Biotech partnerships Patients at risk of Alzheimer's

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Support Program €10.00K 1
EIT Health
01 Jan 2022
Seed €2.30M -
01 Jul 2021
Support Program Undisclosed 1
EIT Health
01 Dec 2020
Seed $490.00K 1
Bernard Majoie
01 Jul 2018
Support Program Undisclosed 1
HEC Paris Incubator
01 Mar 2018

AgenT Alternatives & Competitors

View All Alternatives
AgenT vs
Cyted Health
Cyted Health United Kingdom

Transforming access to digestive health for everyone, everywhere.

Non Equity Assistance
74 employees
AI, Biotechnology
Compare AgenT vs Cyted Health
AgenT vs
PrognomiQ Inc
PrognomiQ Inc United States

Transform healthcare and early disease detection through the power of multi-omics data.

44 employees
Biopharma, Biotechnology
Compare AgenT vs PrognomiQ Inc
AgenT vs
Yaqrit
Yaqrit United Kingdom

The Liver Disease Company

Convertible Note
14 employees
Biotechnology, Health Care
View all alternatives

FAQ About AgenT

Detect Alzheimer's earlier, when it could be prevented
AgenT was founded in 2018.
AgenT is headquartered in France.
AgenT operates in Biotechnology, Health Care and Life Sciences. Its work centres on Life Sciences, Alzheimer's Disease, Multi-omics Assays and Blood Biomarkers. Its customers include Healthcare providers, Neurologists and Clinical researchers.
AgenT has a B2B, D2C and B2D business model. Its revenue comes from Service Fee, Licensing and Data Monetization.
AgenT has approximately 39 employees.
AgenT has completed 5 funding rounds, raising a total of $2.80M.
AgenT offers: Blood test development for early Alzheimer's detection, Machine learning modeling for disease analysis, Multiomics biomarker research.
Top alternatives and competitors to AgenT include Cyted Health, PrognomiQ Inc, Yaqrit, Ensoma, AMONETA DIAGNOSTICS. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AgenT and Cyted Health are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for AgenT, https://bouncewatch.com/company/agent, updated 28 January 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes